Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Asthenia and BRCA1[original query] |
---|
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic oncology 2017 9 147 (2): 267-275. Oza Amit M, Tinker Anna V, Oaknin Ana, Shapira-Frommer Ronnie, McNeish Iain A, Swisher Elizabeth M, Ray-Coquard Isabelle, Bell-McGuinn Katherine, Coleman Robert L, O'Malley David M, Leary Alexandra, Chen Lee-May, Provencher Diane, Ma Ling, Brenton James D, Konecny Gottfried E, Castro Cesar M, Giordano Heidi, Maloney Lara, Goble Sandra, Lin Kevin K, Sun James, Raponi Mitch, Rolfe Lindsey, Kristeleit Rebecca |
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific reports 2021 2 11 (1): 4433. Poveda Andres, Oaknin Ana, Romero Ignacio, Guerrero-Zotano Angel, Fariñas-Madrid Lorena, Rodriguez-Freixinos Victor, Mallol Pedro, Lopez-Reig Raquel, Lopez-Guerrero Jose Anton |
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecologic oncology 2022 1 164 (3): 498-504. Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez M J Rubio, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: